MIRM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MI

Mkt Cap

$5.20B

Volume

325.46K

Next Earnings

November 3rd

Loading chart

MI

MIRMMirum Pharmaceuticals, Inc. Common Stock

MIRM

Pay with—

Available Balance0.00

MI

Mkt Cap

$5.35B

Volume

325.46K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesMirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.Zacks Investment Research · Oct 13, 2026

Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDVMirum Pharmaceuticals announced that brelovitug met the primary endpoint in the phase III AZURE-1 study for chronic hepatitis delta virus (HDV) treatment. 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks achieved virologic response and ALT normalization compared to 0% in the delayed-treatment arm. The drug was well-tolerated with no new safety concerns. Phase III AZURE-4 data are expected in Q4 2026, with a potential BLA submission planned for H1 2027 and commercial launch expected in Q4 2027.Zacks Investment Research · Sep 29, 2026

Arcutis Expands Board of Directors with Appointment of Chris PeetzArcutis Biotherapeutics announced the appointment of Christopher Peetz, CEO of Mirum Pharmaceuticals, to its Board of Directors effective July 15, 2026. Peetz brings extensive biopharmaceutical leadership experience from roles at multiple companies including Onyx Pharmaceuticals and Tobira. The appointment comes as Arcutis continues to expand its ZORYVE (roflumilast) franchise for treating inflammatory skin diseases and evaluates pipeline expansion through strategic acquisitions.GlobeNewswire Inc. · Jul 16, 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.The Motley Fool · Mar 20, 2026

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business AchievementsXOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.GlobeNewswire Inc. · Mar 18, 2026

Is Mirum Pharmaceuticals on a Strong Path to Profitability?Mirum Pharmaceuticals showed profitability in Q3 2025 and strong revenue growth of 56.8% year-over-year through nine months. However, the company faces headwinds including slowing sales growth guidance for 2026 (23.1% vs 54.4% in 2025) and near-term profitability challenges from the $620 million Bluejay Therapeutics acquisition. While the stock has doubled over 12 months, analysts suggest profitability may take several more years to achieve consistently.The Motley Fool · Jan 31, 2026

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the LineEventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals in Q3, but the position's value increased by approximately $50.70 million to $184.92 million due to the stock's 89% surge over the past year. The share reduction appears to be portfolio management rather than a loss of confidence, as Mirum posted strong Q3 revenue growth of 47% and raised full-year guidance, with the company now representing the fund's second-largest equity holding.The Motley Fool · Dec 28, 2025

Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026Mirum Pharmaceuticals has seen nearly 70% stock growth in 2025, with its flagship drug Livmarli driving sales and potential for continued expansion in 2026, supported by promising pipeline candidates volixibat and MRM-3379.The Motley Fool · Dec 3, 2025

Mirum (MIRM) Soars on Interim Data From Liver Disease StudiesMirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.Zacks Investment Research · Jun 18, 2024

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.Zacks Investment Research · Jun 18, 2024

to start trading

MI

MIRMMirum Pharmaceuticals, Inc. Common Stock

MIRM

Pay with—

Available Balance0.00

Your PositionYou don't own any MIRM yet.

Related Tickers

Earnings